Nevertheless, various experiments involving pembrolizumab or nivolumab have indicated relatively modest rates of response (ranging from 10% to 26%) in gastric cancer during the salvage phase, without the presence of any specific biomarker or PD-L1 positivity4. This evidence concerns the gene CD274 and gastric cancer.